Holen Sie sich die Stockscreener-App
6.81
12.19%
0.74
Handel nachbörslich:
6.34
-0.47
-6.90%
Schlusskurs vom Vortag:
$6.07
Offen:
$5.6
24-Stunden-Volumen:
253.52K
Relative Volume:
2.12
Marktkapitalisierung:
$30.26M
Einnahmen:
$36.86M
Nettoeinkommen (Verlust:
$-171.67M
KGV:
-4.54
EPS:
-1.5
Netto-Cashflow:
$-171.05M
1W Leistung:
+1.64%
1M Leistung:
-20.79%
6M Leistung:
-55.29%
1J Leistung:
-79.82%
1-Tages-Spanne:
$5.21
$6.82
1-Wochen-Bereich:
$5.21
$6.82
52-Wochen-Spanne:
$5.21
$70.75
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Firmenname
Mersana Therapeutics Inc
Sektor
Branche
Telefon
617-498-0020
Adresse
840 MEMORIAL DRIVE, CAMBRIDGE
Vergleichen Sie MRSN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
6.81 | 30.26M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | William Blair | Outperform |
| 2024-11-15 | Fortgesetzt | Citigroup | Buy |
| 2024-03-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-29 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-07-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-07-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-27 | Herabstufung | Truist | Buy → Hold |
| 2023-07-27 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-06-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-06-15 | Eingeleitet | Guggenheim | Buy |
| 2023-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-20 | Eingeleitet | Citigroup | Buy |
| 2022-11-21 | Eingeleitet | Truist | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Neutral |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-04-29 | Eingeleitet | BTIG Research | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-14 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Mersana Therapeutics Inc Aktie (MRSN) Neueste Nachrichten
Mersana stock price target raised to $17 from $6 at BTIG - Investing.com Canada
Mersana Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone - MSN
Mersana Therapeutics Q2 2025: Unpacking Key Contradictions in Clinical Strategies and Patient Eligibility - AInvest
Transcript : Mersana Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Mersana Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Mersana Therapeutics Q2 2025 Misses Revenue Forecast - Investing.com Australia
Mersana Therapeutics, Inc. SEC 10-Q Report - TradingView
Mersana Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$3.93 and Revenue of $6.36 Million - GuruFocus
Mersana Therapeutics earnings missed by $4.71, revenue fell short of estimates - Investing.com Canada
Mersana Therapeutics Provides Business Update and Announces Seco - GuruFocus
Mersana Therapeutics Q2 2025 Financial Results and Business Update - TradingView
Mersana's Cancer Drug Trial Hits Major Enrollment Milestone, Reports $77M Cash Position - Stock Titan
Mersana Therapeutics Q2 2025 Earnings Preview - MSN
Can Traders Expect Breakout From Mersana Therapeutics Inc. This WeekStock Market Watch With Alerts Shows Unusual Activity - 선데이타임즈
Mersana Therapeutics Inc. Uptrend in Early Stages Indicators Say YesInvestment Plan With Growth Optimization Finalized - beatles.ru
Mersana Therapeutics MRSN 2025Q2 Earnings Preview Upside Ahead on Promising Drug Pipeline - AInvest
Revenues Working Against Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Share Price Following 25% Dive - simplywall.st
Is Mersana Therapeutics Inc. still worth holding after the dipAI-Based Reversal Point Prediction Signal - Newser
Will Mersana Therapeutics Inc. outperform the marketPattern Recognition Tool for ROI Investors - Newser
Will Mersana Therapeutics Inc. stock go up soonBuy and Hold Strategy for Capital Safety - Newser
Mersana Therapeutics Inc.’s volatility index tracking explainedFree Entry Alert Based on Volume Spikes - Newser
Competitive Positioning of Mersana Therapeutics Inc.: Is It Leading or LaggingGrowth Watchlist for Long Term Positioning - Newser
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 | MRSN Stock News - GuruFocus
Mersana Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewswire
Leading Cancer ADC Developer Mersana Therapeutics Reveals Q2 2025 Earnings Date: Pipeline Updates Expected - Stock Titan
Mersana Therapeutics (NASDAQ:MRSN) Cut to “Strong Sell” at Wall Street Zen - Defense World
Ranking Mersana Therapeutics Inc. among high performing stocks via toolsTrading Volume Anomaly Summary and Insight - Newser
What are analysts’ price targets for Mersana Therapeutics Inc. in the next 12 monthsAchieve breakthrough gains with expert advice - Jammu Links News
Mersana Therapeutics Inc. Recovers — But Is It SustainableStock Portfolio Allocation Guidance for Volatile Markets - beatles.ru
Should I hold or sell Mersana Therapeutics Inc. stock in 2025Gain the edge with real-time market data - Jammu Links News
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionFree Stock Selection With High Accuracy - Newser
Does Mersana Therapeutics Inc. stock perform well during market downturnsExponential return rates - Jammu Links News
What are the latest earnings results for Mersana Therapeutics Inc.Invest confidently with professional guidance - Jammu Links News
How does Mersana Therapeutics Inc. generate profit in a changing economyRapidly expanding wealth - Jammu Links News
When is Mersana Therapeutics Inc. stock expected to show significant growthCapitalize on strong market momentum - Jammu Links News
How does Mersana Therapeutics Inc. compare to its industry peersGet timely alerts on top-performing stocks - Jammu Links News
Why is Mersana Therapeutics Inc. stock attracting strong analyst attentionRapid market gains - Jammu Links News
How volatile is Mersana Therapeutics Inc. stock compared to the marketIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Mersana Therapeutics Inc. stockRetirement Planning Insights For 2025 - Jammu Links News
How strong is Mersana Therapeutics Inc. company’s balance sheetStock Strategy Insights For Fast Growth - Jammu Links News
How Mersana Therapeutics Inc. stock performs during market volatilityShort Term Alpha Signals Review - beatles.ru
Full technical analysis of Mersana Therapeutics Inc. stockPortfolio Positioning Strategy With Timing - Newser
Mersana Therapeutics shares fall 4.45% intraday despite positive clinical data and price target increase. - AInvest
Will Mersana Therapeutics Inc. benefit from macro trendsGrowth Based Investment Plan Guidance Highlighted - metal.it
Published on: 2025-07-30 03:04:39 - metal.it
Published on: 2025-07-29 23:14:19 - metal.it
Will Mersana Therapeutics Inc. stock split in the near futureBreakout Stocks Insights To Watch Now - Jammu Links News
Mersana Therapeutics Inc. Sees Spike in Bullish Option FlowStable Entry High Return Opportunities in Focus - beatles.ru
Finanzdaten der Mersana Therapeutics Inc-Aktie (MRSN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):